Navigation Links
Nonin Medical, Inc. Receives Frost & Sullivan's 2007 Award for Product Differentiation Innovation
Date:12/19/2007

MINNEAPOLIS, Dec. 19 /PRNewswire/ -- Nonin Medical, Inc., a leading innovator of physiological monitoring solutions, received the 2007 Industry Best Practices Award for Product Differentiation Innovation from Frost & Sullivan. Frost & Sullivan recognizes outstanding industry achievements and the Awards are recognized worldwide by the media, the investment community and end-user markets. The global growth consulting company honored Nonin for its pioneering vision that has transformed the vital sign monitoring industry and brought powerful, portable and easy-to-use pulse oximetry technology to more people and applications worldwide.

"Nonin's PureSAT(R) signal processing and PureLight(R) sensor technologies offer unparalleled blood oxygen saturation level recording and analysis by eliminating the effect of low perfusion and motion artifacts," said the Frost & Sullivan report. With its patented PureSAT technology built into every device, Nonin's robust technology delivers accurate performance in both acute care and alternate care environments.

With well over 1 million oximeters sold worldwide, "Nonin Medical has not only set new standards, but also released the untapped potential in a variety of markets," the report from Frost & Sullivan states. A number of Nonin's innovative "firsts" include the world's first self-contained fingertip oximeter, the first low power handheld oximeter and the first Bluetooth(R) Wireless Oximeter. Because of their accuracy, small size and portability, Nonin's oximeters have opened up a whole new direction in patient care in both acute care and alternate care markets.

As one of the Founding Promoters of the Continua Health Alliance(SM) and a member of the Bluetooth(R) SIG, Nonin has joined hands with some of the finest healthcare and technology companies to improve patient care. These organizations are committed to connecting technology and people through the facilitation of interoperable solutions and information exchange. CEO Gary Tschautscher, also recognized by Frost & Sullivan as CEO of 2007 in North American Patient Monitoring, adds, "We believe the future brings a streamlined environment that eliminates proprietary interfaces and facilitates interoperability with other medical equipment. Given the rise of chronic conditions and an aging population, Nonin is focusing on how patient care is evolving from traditional clinical settings to everyday environments, including the home." Nonin's vision for the future is to continue its leadership in offering a wide range of medical solutions to simplify patient care.

About Nonin Medical, Inc. - http://www.nonin.com

Minneapolis-based Nonin Medical, Inc., a privately owned company specializing in the design and manufacture of physiological monitoring solutions, distributes its branded and OEM products to health and medical professionals in more than 125 countries. Since 1986, Nonin has developed a broad product line of pulse oximeters, capnographs, sensors, accessories and software for use by medical professionals. Its industry-leading capabilities in signal processing, sensor design and an innovative combination of features not available in competitive products are the foundation of its leadership in innovation.

About Frost & Sullivan - http://www.frost.com

Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.awards.frost.com.


'/>"/>
SOURCE Nonin Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
2. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):